GFPC
RNAC icon

Global Financial Private Client’s Cartesian Therapeutics RNAC Stock Holding History

Global Financial Private Client’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,000
Closed – – 1296
2025
Q1 		$0 Buy
+1,000
New +$17.9K ﹤0.01% 1696

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Global Financial Private Client's RNAC Position: Q2 2025 in Review

Global Financial Private Client sold out of Cartesian Therapeutics (RNAC) in Q2 2025, closing a stake of 1,000 shares.

Global Financial Private Client first reported a position in RNAC in Q1 2025 and held it in 1 quarter. The position peaked at $0 in Q1 2025. 66 funds tracked by Wall St. Rank hold RNAC as of Q2 2025.

  • Global Financial Private Client reported no remaining Cartesian Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Global Financial Private Client sold 1,000 Cartesian Therapeutics shares in Q2 2025.
  • Global Financial Private Client first reported a position in Cartesian Therapeutics in Q1 2025 and held it in 1 quarter.
  • Global Financial Private Client's Cartesian Therapeutics position peaked at $0 in Q1 2025.
  • 66 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2025.

Based on Global Financial Private Client's 13F filing for Q2 2025, filed 10 Jul 2025.